Department of Cardiology, University Hospital Basel, Basel, Switzerland.
Can J Cardiol. 2012 Jul-Aug;28(4):516.e5-7. doi: 10.1016/j.cjca.2012.01.023. Epub 2012 Apr 4.
The safety of percutaneous transapical mitral paravalvular leak (PVL) closure could potentially be enhanced by device closure of the ventricular access site. Percutaneous transapical PVL closure was performed. The 9F delivery sheath was pulled back, and a 6-mm Amplatzer muscular ventricular septal defect occluder was deployed at the apical puncture site. Immediate hemostasis was achieved. Total hospitalization was 9 days. New York Heart Association functional class was improved, hemoglobin and haptoglobin rose, while lactate dehydrogenase fell. Follow-up fluoroscopy and transthoracic echocardiography revealed a good functional result. Closure of the apical access site by means of an Amplatzer muscular ventricular septal defect occluder is feasible.
经皮心尖部二尖瓣瓣周漏（PVL）封堵术时，通过器械封闭心室入路部位可提高安全性。实施了经皮心尖部二尖瓣瓣周漏封堵术。将 9F 输送鞘管后撤，在心尖穿刺部位释放 6 毫米 Amplatzer 肌部室间隔缺损封堵器。即刻止血成功。总住院时间为 9 天。纽约心脏协会（NYHA）心功能分级改善，血红蛋白和触珠蛋白升高，而乳酸脱氢酶下降。随访透视和经胸超声心动图显示良好的功能结果。使用 Amplatzer 肌部室间隔缺损封堵器封闭心尖部入路部位是可行的。
